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Abstract
Background: Polysaccharides extracted from the Phellinus linteus (PL) mushroom are known to possess anti-tumor
effects. However, the molecular mechanisms responsible for the anti-tumor properties of PL remain to be explored.
Experiments were carried out to unravel the anticancer effects of PL.
Methods: The anti-cancer effects of PL were examined in SW480 colon cancer cells by evaluating cell proliferation,
invasion and matrix metallo-proteinase (MMP) activity. The anti-angiogenic effects of PL were examined by
assessing human umbilical vein endothelial cell (HUVEC) proliferation and capillary tube formation. The in vivo
effect of PL was evaluated in an athymic nude mouse SW480 tumor engraft model.
Results: PL (125-1000 μg/mL) significantly inhibited cell proliferation and decreased b-catenin expression in SW480
cells. Expression of cyclin D1, one of the downstream-regulated genes of b-catenin, and T-cell factor/lymphocyte
enhancer binding factor (TCF/LEF) transcription activity were also significantly reduced by PL treatment. PL
inhibited in vitro invasion and motility as well as the activity of MMP-9. In addition, PL treatment inhibited HUVEC
proliferation and capillary tube formation. Tumor growth of SW480 cells implanted into nude mice was significantly
decreased as a consequence of PL treatment, and tumor tissues from treated animals showed an increase in the
apoptotic index and a decrease in b-catenin expression. Moreover, the proliferation index and microvessel density
were significantly decreased.
Conclusions: These data suggest that PL suppresses tumor growth, invasion, and angiogenesis through the
inhibition of Wnt/b-catenin signaling in certain colon cancer cells.
Background
Colorectal cancer (CRC) is the third most prevalent
form of cancer in men and women, with a 5-year survi-
val rate of 63%, decreasing to 10% in patients with
metastatic disease [1]. Thus, the formation of distant
metastasis is the decisive and most lethal event during
the course of the disease. Although recent advances in
chemotherapeutic agents in CRC have been achieved,
treatment options are still limited and are associated
with significant morbidity and mortality.
Mushroom polysaccharides are widely being used as
nonspecific immunostimulants for cancer patients in
Asian countries. The Polysaccharide isolated from Phelli-
nus linteus (PL) is an immunomudulatory agent with a
molecular weight of 153 kDa [2]. PL stimulates the prolif-
eration of T lymphocytes and activates B cells [3], induces
secretory and celluar macrophage response [4], and inhi-
bits tumor growth and metastasis through the immunopo-
tentiation [5]. It had been suggested that antitumor effect
are not only immunomodulatory, but may result from a
direct action on tumor cells.
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We previously demonstrated that PL has an antiproli-
ferative effect for SW480 colon cancer cells and the
growth inhibition is mediated by induction of apoptosis
and G2/M cell cycle arrest which are associated with
decrease in Bcl-2, increase of the release of cytochrome
c, and reduced expression of cyclin B1 [6]. Since our
report, the direct antitumor effect of PL has been
demonstrated by others: the inhibition of pulmonary
metastasis of melanoma cells through the downregula-
tion of mRNA level of urokinase plasminogen activator
(uPA) [7], suppressed proliferation of lung cancer cells
by the inhibition of cyclin-dependent kinases cdk2, 4,
and 6, and induced apoptosis through the activation of
caspase 3 [8], apoptosis of prostate cancer cells [9,10],
and inhibition of tumor growth and invasive behavior of
breast cancer cells mediated by cell cycle arrest at S
phase and inhibition of serine-threonine kinase AKT
signallig [11].
One important signaling pathway involved in the etiol-
ogy of colon cancer is Wnt/b-catenin, and more than
90% of colon cancers bear mutations that result in the
activation of this pathway [12]. Activating mutations in
genes of the Wnt/b-catenin signaling pathway are
observed early in the development of colon cancers.
Mutations that activate the Wnt/b-catenin pathway gen-
erally affect b-catenin phosphorylation and stability [13].
Phosphorylated b-catenin is degraded via the ubiquitin
pathway. In the absence of efficient degradation such as
genetic mutations of adenomatous polyposis coli (APC)
or b-catenin, b-catenin accumulates and is transported
to the nucleus, where it acts as a transcription factor in
concert with T-cell factor/lymphocyte enhancer binding
factor (TCF/LEF) [14,15]. The resulting b-catein-TCF/
LEF complex activates TCF target genes which affect
cell proliferation, survival, angiogenesis, invasion and
metastasis [16]. Recent evidences suggested that
although mutations of components of the Wnt/b-cate-
nin pathway generally occur early in colon cancer pro-
gression, accumulation of b-catenin in the nucleus has
been associated with late stages of tumor progression
and the development of metastasis [17-19].
In the present study, we have investigated the effects
of a PL treatment on multiple steps involved in colon
cancer growth, invasion and neoangiogenesis. Herein,
we show that PL inhibits proliferation, motility and
invasion as well as matrix metalloproteinases (MMPs)
and tumor neoangiogenesis of SW480 colon cancer cells
in vitro and in vivo. Furthermore, we demonstrated that
PL significantly inhibited Wnt/b-catenin signaling
pathway.
Our data suggest that the PL-induced down-regulation
of Wnt/b-catenin signaling may contribute to the inhibi-
tion of tumor growth, invasion and angiogenesis of
SW480 colon cancer cells.
Methods
Cell lines and culture conditions
SW480 human colon cancer cells and HT1080 fibro-sar-
coma cells were obtained from American Type Culture
Collection (ATCC, Rockville, MD). The cells were grown
in Dulbecco’s Modified Eagle’s Medium (DMEM) contain-
ing 10% fetal bovine serum (FBS), penicillin (100 U/mL),
and streptomycin (100 μg/mL). Cultures were maintained
at 37°C in a humidified 5% CO2 atmosphere. PL (Hankook
Sin Yak Pharm., Nonsan, Korea) was dissolved in DMEM
and adjusted to the indicated final concentrations with cul-
ture medium before use. Human umbilical vein endothelial
cells (HUVECs) were isolated from fresh umbilical cords
obtained by caesarean section by a modification of the
technique previously described [20]. HUVECs were cul-
tured in gelatin-coated plates with Endothelial Basal Med-
ium-2 (EBM-2) supplemented with 10 mL FBS, 0.2 mL
hydrocortisone, 2 mL human fibroblast growth factor-basic
(hFGF-B), 0.5 mL vascular endothelial growth factor
(VEGF), 0.5 mL R3-IGF-1, 0.5 mL ascorbic acid, 0.5 mL
human epidermal growth factor (hEGF), 0.5 mL GA-1000,
0.5 mL heparin (EBM-2 Bullet kit, Clonetics) and incu-
bated at 37°C in a humidified incubator containing 5%
CO2. HUVECs were used at passages 2-5.
Cell proliferation assay
The effect of PL on the growth of colon cancer cells was
evaluated using 5 × 103 cells seeded onto 96-well plates
(Corning, NY), which were treated with PL simultaneously
at the time of cell plating. To evaluate the effect of PL at
concentrations 125, 250, 500, and 1,000 μg/mL, cells were
maintained in media with various concentrations of PL for
up to 96 h and cell numbers were determined by a tetrazo-
lium-based colorimetric assay (MTT, Sigma, St. Louis,
MO) [21], and absorbance was read at 570 nm.
Preparation of cell lysates and western blot analysis
Proteins were extracted with RIPA buffer (50 mM Tris-
HCl, pH7.5, 150 mM NaCl, 5 mM ehylenediaminetetraa-
cetic acid [EDTA], 1% Nonidet P-40, 0.1% sodium dodecyl
sulphate [SDS], and 1% sodium deoxycholate) containing
protease inhibitor cocktail tablets (Roche Diagnostics
Indianapolis, IN). Samples were resolved through a 10%
SDS-polyacrylamide gel and transferred to Hybond ECL
membranes (Amersham Pharmacia Biotech, Buckingham-
shire, UK). Membranes were blocked in 1× TBS (1 L of
10× TBS was prepared by mixing 24.2 g of Trizma base
and 80 g NaCl, and the pH was adjusted to 7.6), contain-
ing 0.1% Tween 20 with 5% non-fat skim milk, for 1 h at
room temperature and incubated with a primary antibody
for 1 h at room temperature. After 3 washes (5 min each)
in TBST (TBS containing 0.1% Tween 20), the membranes
were incubated with horseradish peroxidase-conjugated
secondary antibody for 1 h at room temperature. After 3
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washes (5 min each) in TBST, proteins were visualized
using the enhanced chemiluminescence method (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK).
Immuno-cytochemical analysis
Cells were grown to 60% confluence on 12-well cham-
ber slides. The cells were treated with PL for 24 h
before simultaneous paraformaldehyde fixation and per-
meabilisation with Triton X-100. After blocking with 1%
bovine serum albumin (BSA), the cells were incubated
with anti-b-catenin antibody (Santa Cruz Biotechnolgy,
CA) overnight at 4°C. The cells were labeled with Alexa
Fluor 488-conjugated anti-mouse secondary antibody
(Molecular Probes, Eugene, Oregon, USA). The slides
were covered with a mounting solution (Dako, Carpin-
teria, CA) and photos were obtained using an LSM5
confocal microscope (Carl Zeiss, Inc., Jena, Germany).
Luciferase reporter activity
Cells were seeded and allowed to achieve 80% conflu-
ence in 6-well plates. The cells were transiently trans-
fected with 1 μg per well of TCF/LEF-Luc by using
Lipofectamine Plus transfection reagents (Invitrogen,
Carlsbad, CA), according to the manufacturer’s instruc-
tions. After transfection, the cells were treated with var-
ious concentrations of PL for 24 h. Cell lysates were
prepared using 1× reporter lyses buffer (Promega, Madi-
son, WI). Luciferase activity was measured as previously
described, by using an AutoLumat LB953 Luminometer
(Berthold, Stevenage, UK) and using the luciferase assay
system from Promega [22,23]. The relative luciferase
activity was calculated after normalization of cellular
proteins. All values are expressed as the percentage of
activity relative to basal activity.
In vitro invasion and motility assay
Transwell culture chambers containing polycarbonate
filters of diameter 6.5 mm and pore size 8 μm (Costar,
Cambridge, MA) were used for the assay according to a
previously described method [24]. For the invasion
assay, filters coated with Matrigel (160 μg per filter)
were used. To investigate the effect of PL on invasion,
we added various concentrations of PL to the media.
After 72 h of incubation, cells on the top of the filter,
which was generated by non-invasive cells, were
removed using cotton swabs. The filters were removed,
and the invasive cells beneath the filters were stained
with Gill’s hematoxylin and counted under a micro-
scope. For the motility assay, the same system was used,
but the Matrigel coating was omitted.
Protease analysis by substrate-embedded gel
For zymography analyses [25], cells grown to 80% conflu-
ence were washed 3 times with calcium-magnesium-free
phosphate-buffered saline (PBS) and cultured in DMEM
without FBS. Conditioned media (CM) were obtained
after 24 h of culture and centrifuged at 3,000 × g for
10 min to remove cells and debris. Cell-free CM was con-
centrated approximately 10-fold by using a Centricon-10
device (Amicon, Beverly, MA), and aliquots of the con-
centrated CM were normalized for cell number. Proteins
in the normalized CM were then separated by electro-
phoresis on 10% polyacrylamide gels impregnated with
1 mg/mL gelatin (Fisher Chemical Co., Fair Lawn, NJ) or
1 mg/mL casein (Sigma Chemical Co.) containing 13 μg/
mL plasminogen (Sigma Chemical Co.) under non-
reducing conditions. After electrophoresis, the gels were
washed twice in 2.5% Triton X-100 for 30 min, proteo-
lysed with a reaction buffer (50 mM Tris-HCl, 5 mM
CaCl2, and 0.02% NaN3 [pH 8.0]) for 72 h at 37°C, and
stained with Coomassie Brilliant Blue G-250. To investi-
gate the effect of PL on proteases, we added various con-
centrations of PL to the incubation buffer.
HUVEC proliferation and capillary tube formation on
matrigel
Growth assays of HUVECs were carried out according
to the procedure described by Bae et al. [24], with some
modifications. Briefly, HUVECs were seeded in 0.2%
gelatin-coated wells in a 96-well culture plate (Corning,
NY) at an initial density of 5 × 103 cells/well in 200 μL
of EBM-2 and then grown under standard conditions at
37°C in 5% CO2. On the next day, 125, 250, 500, and
1,000 μg/mL of PL were added to each well for 3 d, and
the number of viable cells was measured using the MTT
assay. To further assess the anti-angiogenic effect of PL,
we performed vascular tube formation experiments.
HUVECs were seeded at a density of 104 cells/well in
Matrigel-coated 24-well plates and incubated at final PL
concentrations of 250, 500, and 1,000 μg/mL. During
these incubations, HUVEC morphological changes were
monitored using an inverted phase-contrast microscope
(Model IX 70; Olympus, Tokyo, Japan) and photographs
were obtained.
Nude mice tumourigenicity
All animal-related procedures were reviewed and
approved by the Institutional Animal Care and Use Com-
mittee of Chungnam National University. Confluent colon
cancer cell cultures were harvested by brief trypsinization,
washed 3 times with calcium and magnesium-free PBS,
and re-suspended at a final concentration of 5 × 107 cells/
mL in serum-free DMEM. Single-cell suspensions were
confirmed by phase-contrast microscopy, and cell viability
was determined using trypan blue exclusion; only single-
cell suspensions with a viability > 90% were used. Patho-
gen-free female BALB/cAnNCrj-nu athymic nude mice (4
weeks old; Charles River Laboratories, Kanazawa, Japan)
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were anesthetized with diethyl ether by inhalation, and 5 ×
106 SW480 cells in serum-free DMEM were inoculated
subcutaneously (s.c.) into the right flank. From the day of
tumor cell inoculation, the mice received a daily intratu-
moral injection (i.t.) of PL (100 μg/100 μL of saline) or
intravenous injection (i.v.) of PL (25, 50, 100 μg/100 μL of
saline) as well as the same amount of physiologic saline as
a control for 14 d. The mice were regularly examined,
tumor sizes were measured with a caliper, and tumor
volumes were determined using the following formula:
volume = 0.5 × (width)2 × length [26]. Each experimental
group consisted of 8 animals.
Immuno-histochemical analysis
The mice were euthanized and tumors were removed and
bisected. One part of the tumor was placed in neutral buf-
fered formalin for paraffin block preparation, and the
other part was frozen for preparation of cryo-cut sections.
The degree of apoptosis was evaluated using an ApopTag
apoptosis detection kit (S7101; Intergen, Norcross, GA),
according to the manufacturer’s recommendations. The
apoptotic index was calculated as the percentage of nuclei
stained by peroxidase, showing nuclear halo or apoptotic
bodies. Positive cells were quantified by counting the
number of brown-stained nuclei/total number of cells in 5
randomly selected 400× magnified fields.
To evaluate the proliferation index, the paraffin sections
were incubated with a monoclonal mouse Ki-67 antibody
(MIB-1; Dako, Carpinteria, CA) at a dilution of 1:100.
Staining was carried out with a universal labeled streptavi-
din-biotin kit (Dako, Carpinteria, CA), according to the
standard protocol. The proliferation index was determined
by counting stained cells at 400×. To immuno-localize
tumor blood vessels, the cryo-sections were stained with a
monoclonal rat anti-mouse CD31 antibody (PECAM-1;
BD PharMingen, San Diego, CA) at a dilution of 1:50. The
antigen-antibody reaction was visualized using an anti-
mouse immunoglobulin horseradish peroxidase detection
kit (BD PharMingen, San Diego, CA), according to the
manufacturer’s recommendations. Vessel density was
determined by counting the Positive cells were quantified
by counting the standard vessels in 5 randomly selected
200× magnified fields.
To confirm tissue b-catenin levels, paraffin sections
were de-parafinised in xylene and dehydrated in serially
diluted ethanol. Antigen retrieval was performed using
citrate buffer (pH 6.0). The sections were blocked with a
protein blocker (Dako, Carpinteria, CA) and stained
with an anti-b-catenin antibody (Santa Cruz Biotechnol-
ogy, CA). The sections were then stained with hematox-
ylin and photographed under a light microscope.
Positive cells were quantified by counting the number of
brown-stained cells/total number of cells in 5 randomly
selected 400× magnified fields
Statistical analysis
Data are expressed as mean and standard deviation
(SD), and significance was established by unpaired Stu-
dent’s t test. For all analyses, the level of statistical sig-
nificance was more than the 95% confidence level (P <
0.05). *, **, or *** indicates P < 0.05, P < 0.01, or P <
0.001, respectively.
Results and Discussion
PL inhibited cell proliferation and Wnt/b-catenin signaling
pathway activity in SW480 colon cancer cells in vitro
Although the growth inhibitory effect of PL has been
reported in different types of cancers, including colorec-
tal cancer [4-11], the molecular mechanisms responsible
for the anti-tumor and anti-invasive behavior of PL
remain elusive.
SW480 colon cancer cells, which are characterized by
b-catenin over-expression and a mutant APC (25), were
used to evaluate the effect of PL on cell proliferation by
the MTT assay. PL was added to the SW480 cell culture
medium at the time of plating and maintained for 24, 48,
72, and 96 h. Treatment with PL (125-1,000 μg/mL)
resulted in a significant dose-dependent inhibition of cell
proliferation (Figure 1A, P < 0.001). Furthermore, cell pro-
liferation was almost ceased when 250-1,000 μg/mL of PL
was added. These results indicate that PL inhibits the pro-
liferation of SW480 cells, as previously reported [6].
The intracellular levels of b-catenin are tightly regulated
by its degradation complex composed of APC, glycogen
synthase kinase-3b (GSK-3b), and Axin [27]. Moreover,
APC controls the sub-cellular localization of b-catenin by
nuclear-cytoplasmic shuttling [28]. Loss of functional APC
protein leads to the inappropriate stabilization of b-catenin
[29]. In virtually all cases of colon cancer, mutations target
components of the Wnt/b-catenin signaling pathway [30].
We examined the potential effect of PL on b-catenin pro-
tein level and activity in SW480 cells, since these cells are
reported to carry mutations of APC and over-express
b-catenin [31]. As shown in Figure 1B, treatment with PL
reduced the levels of b-catenin protein as well as cyclin
D1, a downstream-regulated gene of b-catenin, in a dose-
dependent fashion. This result indicates that PL effectively
inhibits the accumulation of b-catenin and the expression
of its downstream genes.
The functions of b-catenin are determined by its sub-
cellular distribution. In general, b-catenin localizes to the
cytoplasm or nucleus with a preference for the peri-
plasma membrane, where it binds to E-cadherin. In cells
over-expressing b-catenin, as in the majority of colon
cancer cells, the protein is predominantly present in a
de-phosphorylated form and translocates into the
nucleus, activating the transcription of target genes [30].
In the present study, the effect of PL on the intracellular
localization of b-catenin was evaluated using indirect
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immuno-fluorescence analysis after PL treatment. Under
control conditions, b-catenin was detected in the cyto-
plasm and nucleus, but preferentially accumulated in the
nucleus. Cells treated with PL showed a remarkable
decrease of b-catenin staining in both cytoplasm and
nucleus (Figure 1C).
Because b-catenin regulates gene expression by forming
a complex with TCF/LEF transcription factor family pro-
teins and binding to the promoter region of target genes,
we further examined the effect of PL on TCF/LEF reporter
activity. TCF/LEF transcriptional activity was assayed after
transient transfection of a luciferase reporter construct
under the control of a TCF/LEF response element. As
shown in Figure 1D, PL treatment significantly inhibited
TCF/LEF reporter activity in a dose-dependent fashion (P
< 0.001). This result strongly suggests that PL modulates
the Wnt/b-catenin signaling pathway.
PL inhibited the invasion and motility of SW480 cells and
the secretion of MMP-2 and MMP-9 from SW480 cells
Tumor cell invasion and metastasis are multistep phe-
nomena involving the proteolytic degradation of the
basement membrane and extracellular matrix (ECM),
altered cell adhesion, and physical movement of tumor
cells [20]. Although the correlation between b-catenin
expression patterns and clinical outcome is somewhat a
controversial subject, there are studies reporting that
positive nuclear expression of b-catenin at the invasive
front of colorectal carcinomas predicts shorter survival
[32,33]. Current studies provide evidence that activation
of Wnt/b-catenin signaling is associated with increased
expression of MMPs, which are key enzymes involved in
invasion and metastasis, in endothelial cells [34], chon-
drocytes [35], and cancer cells [36,37]. To determine
whether PL affects the invasive ability of human colon
Figure 1 PL inhibited cell growth and Wnt/b-catenin signaling in SW480 human colon cancer cells. A, SW480 cells were treated with
various concentrations of PL for the indicated times. At the indicated time points, cell growth was measured by the MTT assay as described in
Methods. The data represent the mean of three independent experiments ± SD. ***, P < 0.001 versus control. B, Cells were treated with various
concentrations of PL (125-500 μg/mL). After 24 h, protein samples were prepared and each sample was electrophoresed in an SDS-PAGE gel and
immuno-blotted to detect b-catenin and cyclin D1. The blots shown are representative of three independent experiments with similar results. C,
SW480 cells were treated with PL (250 μg/mL) and immuno-stained for b-catenin. Representative images were obtained by confocal microscopy.
D, SW480 cells transiently transfected with p-luc TCF/LEF and treated with the indicated concentrations of PL. Luciferase reporter activity was
measured in cell extracts after 16 h of PL treatment. Error bars, SD (n = 3). ***, P < 0.001 versus control.
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cancer cells in vitro, we performed invasion and motility
assays by using various concentrations of PL. Treatment
with 125, 250, and 500 μg/mL of PL significantly inhib-
ited invasion of SW480 cells in a dose-dependent man-
ner (28.6%, 53.5%, and 80.2%, respectively; P < 0.001;
Figure 2A). In addition, cell motility was significantly
inhibited by increasing PL concentrations (40.7%, 54.4%,
and 73.5% inhibition with 125, 250, and 500 μg/mL of
PL, respectively; P < 0.001; Figure 2B).
The key enzymes that have been shown to be closely
associated with invasive and metastatic potential are
MMPs and uPA [38,39]. Several studies have shown that
PL inhibits cancer cell invasion and metastasis by
activating host immunity [40-42]. Recently, PL was
shown to suppress invasiveness through the inhibition
of uPA secretion in mouse melanoma cells and breast
cancer cells [7,11]. To evaluate the inhibitory effect of
PL on MMPs and uPA, the CM of SW480 colon cancer
cells and HT1080 fibro-sarcoma cells (as a control for
MMP-9 and MMP-2) were evaluated zymographically.
However, we did not observe any effect of PL on uPA
activity in a casein and plasminogen-impregnated gel
system (data not shown). Moreover, PL treatment did
not affect MMP gene expression or secretion as indi-
cated by reverse transcriptase-polymerase chain reaction
and gelatin zymography (data not shown). Interestingly,
Figure 2 PL inhibited in vitro invasion and motility of SW480 cells and the activity of MMP-9. A, The histogram shows the mean number
of invasive cells for a 20× field of view. Counts were performed on three inserts and five fields of view per insert. Cells were loaded onto
Matrigel-coated upper chambers of Transwell plates and treated with the indicated concentrations of PL; filtrated cells were stained. The error
bars represent the SD of the mean number of invasive cells per field of view for all fields. ***, P < 0.001 versus control. B, Cells were loaded onto
gelatin-coated upper chambers, and filtrated cells were stained. The histogram shows the mean number of invasive cells for a 20× field of view.
Counts were performed on three inserts and five fields of view per insert. The error bars represent the SD of the mean number of invasive cells
per field of view for all fields. ***, P < 0.001 versus control. C, Conditioned media was prepared from SW480 and HT1080 cells and
electrophoresed in a gel containing gelatin. The gels were incubated for 24 h with the indicated concentrations of PL. The gel shown is
representative of three independent experiments with similar results. D, The densities of bands of MMP-2 and MMP-9 were quantified by
imaging densitometry. MMP-2 and MMP-9 activity of the control was set at 100%; the activities of PL-treated samples are represented as
percentages of the control. *, P < 0.05 versus control; ***, P < 0.001 versus control.
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PL inhibited the activity of MMPs without affecting
their expression or secretion. Treatment with 500 and
1,000 μg/mL of PL significantly reduced MMP-9 and
MMP-2 activities in SW480 and HT1080 cells (Figure
2C and 2D). Although the exact mechanism of PL inhi-
bition of MMP-9 and MMP-2 activities is not clear, this
finding provides the first evidence of the potential effect
of PL on the direct inhibition of these gelatinolytic
activities. Taken together, the inhibitory effects of PL on
cellular invasion, in vitro motility, and the activity of
MMPs suggest that PL has a direct anti-invasive effect
on certain colon cancer cells.
Effect of PL on HUVEC growth and capillary tube
formation
Tumor angiogenesis is critical for the growth and
metastasis of solid tumors [24]. Angiogenesis is both
complex and dynamic and requires the proliferation of
endothelial cells from pre-existing blood vessels, break-
down of the ECM, and migration of endothelial cells
[20,43]. To elucidate the anti-angiogenic effect of PL,
HUVEC proliferation and tube formation were investi-
gated. The number of HUVECs cultured on gelatin was
examined by MTT colorimetric assay to determine the
cytotoxic effect of PL. In this experiment, PL was found
to have a significant dose-dependent cytotoxic effect on
the proliferation of HUVECs. The rate of growth inhibi-
tion was 5.2, 40.9, 70.4, and 84.5% at 125, 250, 500, and
1,000 μg/mL of PL, respectively (250, 500, 1000 μg/mL,
P < 0.001; Figure 3A).
The morphological features of HUVECs were also evalu-
ated on Matrigel-coated plates after treatment with var-
ious concentrations of PL. Eighteen hours post-treatment,
control HUVECs had formed an interconnected network
of anastomosing cells, which under a low-power light
microscope had a ‘honeycomb’ appearance (Figure 3B;
control). However, this interconnected network, which
resembled a vessel-like structure, progressively disap-
peared with increasing PL concentrations (Figure 3B; 250-
1,000 μg/mL of PL). These results are consistent with a
recent observation that PL inhibited capillary morphogen-
esis of human aortic endothelial cells [11] and angiogen-
esis in a CAM chick embryo assay [44].
Effect of PL on SW480 human colon cancer cell growth
in vivo
We showed that PL significantly inhibits SW480 cell pro-
liferation in vitro in a dose-dependent manner. Further-
more, treatment with PL down-regulated b-catenin and
cyclin D1 expressions in SW480 cells in vitro. To evaluate
whether PL affects the proliferation of SW480 cells in
vivo, we performed a tumourigenicity assay in nude mice.
Daily i.t. treatment with PL (100 μg/100 μL of saline) for 2
weeks resulted in a significant reduction in SW480 tumor
volume compared with saline-treated controls (74.0%,
80.9%, 86.9%, and 92.1% reduction at 1-, 2-, 3-, and 4-
week post-inoculation, respectively; P < 0.001, Figure 4A).
Interestingly, PL-treated tumors appeared to be in a dor-
mant state during the entire experimental period of 30 d,
even 16 d after PL treatment was discontinued (days 16-
30). The effect of PL on SW480 tumor growth in nude
mice was also evaluated using different routes of adminis-
tration and various doses (25-100 μg per mouse) for 14 d
from the day of tumor inoculation. Daily i.v. PL treatment
at 50 and 100 μg for 14 d significantly reduced SW480
tumor volume. Tumor volume was reduced by 47.5% and
73.4% at 1 week, 44.0% and 75.5% at 2 weeks, 39.9% and
58.4% at 3 weeks, and 33.2% and 52.5% at 4 weeks with PL
concentrations of 50 and 100 μg per mouse, respectively
Figure 3 Effect of PL on proliferation of HUVECs and capillary
tube formation. A, HUVECs were seeded in 0.2% gelatin-coated
wells of 96-well plates at an initial density of 5 × 103 cells/well. On
the next day, the indicated concentrations of PL were added to
each well for 24 h, and cell numbers were determined using the
MTT assay as described in Methods. The data shown represent the
mean ± SD of 3 independent experiments (***, P < 0.001). B, PL
inhibited capillary tube formation by HUVECs on Matrigel. HUVECs
were seeded at a density of 104 cells/well in 1:2-diluted Matrigel-
coated 24-well plates and incubated with the indicated
concentrations of PL. At 18 h, the control HUVECs had formed an
interconnected network of anastomosing cells (which had a
honeycomb appearance), whereas HUVECs treated with PL showed
a significant reduction in tube formation in a dose-dependent
manner. Photomicrographs were taken using an inverted phase-
contrast microscope.
Song et al. BMC Cancer 2011, 11:307
http://www.biomedcentral.com/1471-2407/11/307
Page 7 of 11
(P < 0.001, Figure 4B). However, treatment with a low
dose of PL (25 μg/mice) significantly reduced tumor
volume only after a 2-week treatment period (P < 0.05). It
is worth noting that the tumor volume in mice received i.
t. treatment of PL (100 μg/d) appears to be smaller than
that in mice received i.v. injections (100 μg/d), indicating
that direct i.t. administration of PL is more effective in
inhibiting tumor growth, possibly due to a relatively high
concentration or prolonged release of PL in tumor tissues
resulted from i.t. administration. Together, these results
strongly indicate that PL inhibits tumourigenicity of colon
cancer cells.
Immuno-histochemical analysis of proliferation, apoptosis,
angiogenesis, and b-catenin expression in SW480 tumor
tissues
Histological sections of the SW480 tumor tissues grown
in nude mice for 14 d were analyzed for proliferation,
apoptosis, neo-vascularization, and b-catenin expression
(Figure 5A and 5C). Immuno-histochemical analysis of
cell proliferation (Ki-67) showed a significant dose-
dependent reduction in PL-treated tumors compared
with control tumors (29.3%, 40.3%, and 65.3% reduction
with 25, 50, and 100 μg PL, respectively; P < 0.001, Figure
5B, Ki-67). The apoptotic index was significantly
increased in PL-treated tumors (1.8-, 4.9-, and 6.7-fold
higher than control tumors with 25, 50, and 100 μg of
PL, respectively; P < 0.001, Figure 5B, Apoptosis).
Furthermore, neo-angiogenesis in PL-treated tumors, as
determined by the number of CD31-stained microvessels,
was significantly lower than in control tumors (28.7%,
68.3%, and 80.5% reduction at 25, 50, and 100 μg of PL,
respectively; P < 0.001, Figure 5B, Angiogenesis).
We previously showed that b-catenin is preferentially
accumulated in the cytoplasm and nucleus of SW480
cells, and PL treatment significantly decreases the
amount of b-catenin protein. To confirm this finding in
vivo, we evaluated the changes in the levels of b-catenin
Figure 4 Effect of PL on the growth of human colon cancer cells in nude mice. SW480 colon cancer cells (5 × 106 cells/100 μL) were
injected s.c. into the right flank of the nude mice. From the day of inoculation, the mice were administered a daily i.t. injection of (A) PL (100
μg/100 μL of saline) or i.v. injection of (B) PL (25-100 μg/100 μL of saline). Control mice were injected with the same amount of saline until 1
month after tumor cell implantation. Tumor size was measured with a caliper at the indicated times. The greatest dimension of the tumor and
the 1 perpendicular to it were measured using the caliper and tumor size was calculated as 0.5 × (width)2 × length = tumor volume.
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protein in SW480 tumor tissues in response to PL treat-
ment. As shown in Figures 5C, PL (100 μg/mL) treat-
ment markedly decreased the level of cytoplasmic as
well as nuclear b-catenin protein in SW480 tumor tis-
sues. Moreover, the levels of b-catenin and cyclin D1
protein were also significantly reduced in the PL-treated
tumors (Figure 5D). These results are consistent with
the data obtained in our in vitro experiments.
Conclusions
In conclusion, the present results show that PL isolated
from Phellinus linteus causes a significant reduction in
b-catenin protein levels and the down-regulation of cer-
tain downstream genes in the Wnt/b-catenin pathway in
SW480 colon cancer cells in vitro and in vivo. In
addition, we showed that PL significantly reduces inva-
siveness of SW480 cells through a direct effect on the
activity of cellular MMPs, motility, and angiogenesis,
which are strongly associated with Wnt/b-catenin sig-
naling. The present data suggest that PL can be devel-
oped as an effective therapeutic agent for patients with
colon cancer through its effect on the inhibition of mul-
tiple steps involved in colon cancer growth, invasion,
and neo-angiogenesis by suppression of Wnt/b-catenin
signaling.
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